Menu Search
Equities

Tevogen Bio Holdings Inc

G28:DEU

Tevogen Bio Holdings Inc

Actions
  • Price (EUR)0.78
  • Today's Change-0.065 / -7.69%
  • Shares traded1.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

  • Revenue in USD (TTM)0.00
  • Net income in USD-67.33k
  • Incorporated2024
  • Employees17.00
  • Location
    Tevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
  • Phone+1 (646) 807-8832
  • Fax+1 (302) 655-5049
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TVGN:NMQ since
announced		Transaction
value
Tevogen Bio IncDeal completed29 Jun 202329 Jun 2023Deal completed-92.24%1.41bn
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.